Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the Editor

Comparison between mid-nasal swabs and buccal swabs for SARS-CoV-2 detection in mild COVID-19 patients

Dear Editor,

The use of rapid antigen diagnostics tests (Ag-RDT) has gained widespread acceptance as an alternative method for diagnosis of COVID-19 outside of health care settings. Ag-RDT offer advantages as they can be deployed by members of the general public, which require the use of self-collected specimens. Various authors have reported that saliva is a reliable specimen, alternative to nasopharyngeal and mid-nasal swabs, to detect SARS-CoV-2 infections by RT-PCR.\(^1\)\(^-\)\(^4\)\(^,\)\(^10\) Regarding the use of Ag-RDTs with saliva samples, previous studies have mainly reported limitations on the ability of Ag-RDT for COVID-19 diagnosis in this specimen.\(^5\)\(^,\)\(^6\) These limitations could be derived on the viral load distribution or sample preparation protocols, which might need to be adapted to the rheological properties of saliva. Therefore, even if several commercialized Ag-RDT tests list saliva as a possible specimen, the European centre for Disease Prevention and Control (ECDC) currently only validates tests based on nasal, oropharyngeal, and/or nasopharyngeal specimens.\(^7\)

SARS-CoV-2 variants are characterized by distinct mutations, which impact on disease transmissibility, immune escape, diagnostics and possibly tissue tropism. A preliminary study has proposed that saliva swabs are the preferred sample for Omicron variant detection by RT-PCR.\(^8\) Therefore, during a surge of the Omicron variant in the northern area of Barcelona (Catalonia, Spain), we assessed the performance of buccal swabs containing saliva for SARS-CoV-2 detection by Ag-RDT, using mid-nasal specimens as a reference.

In the context of routine clinical diagnosis of mild COVID-19 patients, we enrolled 300 adults in a study to directly compare mid-nasal swabs and saliva specimens for SARS-CoV-2 detection by Ag-RDT. Participants should not have had any food, drink, tobacco or gum in the 30 min preceding saliva swab collection. Participants were initially instructed to cough 3–5 times, wearing a surgical mask. Buccal and mid-nasal swabs were collected by health workers, and mid-nasal swabs were used as a reference. Each swab specimen was then used for Ag-RDT detection following manufacturer's instructions (tests used: BIOSYNEX COVID-19 Ag BSS [ref SW40006]; FLOWFLEX\(^\mathrm{TM}\) [ref L031–11815]; Panbio COVID-19 Ag Test (Abbott)). When mid-nasal and buccal Ag-RDTs showed discordant results, if the individual consented, a third mid-nasal swab was collected and analysed by RT-PCR. This third swab specimen was placed into a sterile tube containing viral transport media (DeltaSwab Virus) and transported to the Microbiology laboratory of Hospital Germans Trias i Pujol and stored at 2 – 8 °C for up to 24 h before RT-qPCR. RNA was extracted using the STAR Mag reagent (Seegen) for the Microlab Starlet IV or Nimbus platforms (Hamilton life Science Robotics, USA), according to the manufacturer’s instructions. PCR amplification was conducted according to the recommendations of the 2019-nCoV RT-qPCR Diagnostic Panel of the Centers for Disease Control and Prevention (CDC) using the Alplex\(^\mathrm{TM}\) 2019-nCoV assay (Seegene, South Korea) on the CFX96 (Bio-Rad, USA) according to manufacturer’s instruction.

Paired samples were successfully obtained in 300 suspected cases of SARS-CoV-2 infection. Included participants had a mean age of 43.6 years (SD 14.6) and 59.7% were females. 285 (95.0%) participants were asymptomatic. The mean number of symptoms was 3.6 (SD 1.8) and the median time from symptom onset was 2 days (IQR 1–3). The most frequently reported symptoms were headache (65.7%); sore throat (64.3%); cough (61.0%) and rhinorrhea (60.0%).

Of the 300 paired samples, Ag-RDT with the mid-nasal swab detected 139 (46.3%) positive COVID-19 cases. In comparison, buccal swabs showed a sensitivity and specificity of 31.7% (44/139) and 98.8% (159/161), respectively (Table 1). 65 discordant results with positive mid-nasal swabs and negative buccal swabs were tested by RT-qPCR. All samples tested by Rt-PCR resulted positive, with a mean cycle threshold (Ct) of 28.3 (SD 7.3).

In summary, our findings show that mid-nasal swabs have better performance than buccal swabs for detecting SARS-CoV-2 with Ag-RDT tests. Of note, the sensitivity of buccal samples was affected in samples with high viral loads (Ct<33),\(^3\) suggesting that buccal swabs are not sensitive enough to detect individuals at risk of transmission. Regarding the usability of buccal swab samples, due to the previous coughing step and the time required for its collection, they imply a higher exposure of the health worker to the potentially infected person.

Taken together, the existing literature and the results provided in our analysis we advise against the use of buccal specimens for SARS-CoV-2 diagnostics with Ag-RDT.

Funding

The study received support and funded of the Gerencia Territorial Metropolitana Nord, Direcció Atenció Primària Metropolitana Nord, Hospital Universitari Germans Trias i Pujol (Institut Català de la Salut).

Table 1

| Nasal Swab (reference test) | TOTAL |
|-----------------------------|-------|
|                            | Positive | Negative |
| Buccal Swab                 | 44       | 2       |
|                            | 95       | 159     |
| TOTAL                       | 139      | 161     |
|                            | 254      | 300     |

\(https://doi.org/10.1016/j.jinf.2022.02.008\)

0163-4453/© 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Ethics

The study was conducted according to the Helsinki Declaration of the World Medical Association. The study protocol was approved by the Ethics Committee at IDIAP Jordi Gol and the institutional review boards of participating centres (P22/022). All patients provided written informed consent before enrolling the study, which was supervised by an independent data and safety monitoring board.

Data sharing

All data produced in the present study are available upon reasonable request to the authors.

Acknowledgments

We thank the North Metropolitan Management for the support in the development of the project. We thank the personnel from the Centralized Support Unit COVID-19 (UCSC), Primary care emergency centres and Northern Metropolitan Clinic Laboratories for their support in administration, human resources, and supply chain management. The authors declare no conflicts of interest.

References

1. Alemany A, Millat-Martinez P, Ouchi D, Corbacho-Monné M, Bordey AE, Esteban C, et al. Self-collected mid-nasal swabs and saliva specimens, compared with nasopharyngeal swabs, for SARS-CoV-2 detection in mild COVID-19 patients. J Infect 2021;83:709–37.
2. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J Infect 2020;81:e48–50.
3. Wylie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med 2020;383:1283–6.
4. Brotos P, Perez-Argüello A, Laines C, Torrents F, Subirats M P, Saucedo J, et al. Validation and implementation of a direct RT-qPCR method for rapid screening of SARS-CoV-2 infection by using non-invasive saliva samples. Int J Infect Dis 2021;100:363–70.
5. De Marínis Y, Pesola A K, Söderlund Strand A, Norman A, Pernow G, Aldén M, et al. Detection of SARS-CoV-2 by rapid antigen tests on saliva in hospitalized patients with COVID-19. Infect Ecol Epidemiol 2021;11.
6. Asai N, Sakamushi D, Ohashi W, Nakamura A, Kawamoto Y, Miyazaki N, et al. Efficiency and validity of automated quantitative chemiluminescent enzyme immunoassay for SARS-CoV-2 antigen test from saliva specimen in the diagnosis of COVID-19. J Infect Chemother 2021;27:1039–42.
7. ECDC. E.C. for D. P. and C. Considerations for the use of saliva as sample material for COVID-19 testing, May 2021. Stock ECDC 2021.
8. Marais G, Huo A, Niranazadeh A, Doolabh D, Enoch A. Saliva Swabs are the Preferred Sample for Omicron Detection; 2021.
9. La Scalia B, Le Bideau M, Andreoni J, Hoang V T, Grimaldi C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis 2020;39:1059–61.
10. Azzizi Maurino V, Bai A, Dani M, di Aiuto A, Fasano M, et al. Diagnostic salivary tests for SARS-CoV-2. J Dent Res 2021;100:115–23.

Ignacio Blanco1
Laboratori Clinic Metropolitana Nord, Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain

Concepción Violán1
Unitat de Suport a la Recerca Metropolitana Nord, Fundació Institut Universitari per a la recerca a l’Atenció Primària Jordi Gol i Gurnina (IDIAP J Gol), Barcelona, Spain

Clara Suñer
Direcció d’Atenció Primària Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain

Julio García-Prieto
Germans Trias i Pujol Research Institute, Barcelona, Spain

Maria José Argerich
Fight Aids and Infectious Disease Foundation, Barcelona, Spain

Meritxell Rodríguez-Illana
Servei de Microbiologia, LCMN, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain

Nemesio Moreno
Departament de Genètica i Microbiologia, UAB, Cerdanyola, Catalonia, Spain

Pere-Joan Cardona
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

Anna Blanco
Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain

Pere Torán-Monserrat
IrsiCaixa AIDS Research Institute, Barcelona, Spain

Bonaventura Clotet
Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain

Josep M Bonet2, Nuria Prat2
Direcció d’Atenció Primària Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain

*Corresponding author.

E-mail address: iblanco.germanstrias@gencat.cat (I. Blanco)

1 Shared first authorship.
2 Shared last authorship.